Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Studies of Left Ventricular Dysfunction (SOLVD)

This study has been completed.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: October 27, 1999
Last updated: April 14, 2016
Last verified: April 2012
To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.

Condition Intervention Phase
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Heart Failure
Myocardial Ischemia
Drug: enalapril
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: July 1985
Study Completion Date: May 1990
  Show Detailed Description


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000516

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
OverallOfficial: Clarence Davis University of North Carolina
  More Information

Publications: Identifier: NCT00000516     History of Changes
Other Study ID Numbers: 35 
Study First Received: October 27, 1999
Last Updated: April 14, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Ventricular Dysfunction, Left
Ventricular Dysfunction
Pathologic Processes
Vascular Diseases
Arterial Occlusive Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on October 26, 2016